Lori Lawley
Director of Finance/CFO bij LUMOS PHARMA, INC.
Vermogen: 35 287 $ op 31-03-2024
Profiel
Lori Lawley is currently the Chief Financial Officer & Secretary at Lumos Pharma, Inc. Prior to this, she worked as a Vice President-Finance & Controller at NewLink Genetics Corp.
from 2018 to 2020.
She also served as a Senior Manager at Ernst & Young LLP from 2014 to 2015.
Ms. Lawley completed her undergraduate and graduate degrees at McCombs School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LUMOS PHARMA, INC.
0.15% | 01-04-2024 | 12 513 ( 0.15% ) | 35 287 $ | 31-03-2024 |
Actieve functies van Lori Lawley
| Bedrijven | Functie | Begin |
|---|---|---|
| LUMOS PHARMA, INC. | Director of Finance/CFO | 04-07-2021 |
Eerdere bekende functies van Lori Lawley
| Bedrijven | Functie | Einde |
|---|---|---|
| LUMOS PHARMA, INC. | Comptroller/Controller/Auditor | 01-03-2020 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01-04-2015 |
Opleiding van Lori Lawley
| McCombs School of Business | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
| Lumos Pharma, Inc. |
